We develop drug candidates to advance into the clinic with pharmaceutical partners
We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities.
Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.
Our Pipeline
We are inviting pharmaceutical partners to take all current and future candidates to clinical success.
INDICATION
RESEARCH
PRECLINICAL
PHASE I
PHASE II
Therapies for complement disorders
C3 glomerulopathy (C3G)
Complement disorders
Complement disorders
Enzyme replacement therapies
Fabry disease
Pompe disease
Which product can we develop with you?
We look forward to hearing from you!
eleva GmbH
Hans-Bunte-Str. 19
79108 Freiburg
Germany
Phone: +49 761 470 99 0
hello@elevabiologics.com